Is Margin Status Less Prognostic After Neoadjuvant Chemoradiotherapy for Pancreatic Adenocarcinoma?

Ann Surg Oncol. 2022 Jan;29(1):20-22. doi: 10.1245/s10434-021-10885-3. Epub 2021 Oct 15.

Authors

John A Windsor¹, Mark P Callery²

Affiliations

¹ Surgical and Translational Research Centre, The University of Auckland, Building 507-2004, 22-30 Park Avenue, Grafton, 1142, Auckland, New Zealand. j.windsor@auckland.ac.nz.
² Harvard Medical School, 185 Pilgrim Road, Palmer 6, Boston, MA, 02215, USA.

PMID: 34654987
DOI: 10.1245/s10434-021-10885-3

No abstract available

Publication types

Editorial

MeSH terms

Adenocarcinoma* / drug therapy
Chemoradiotherapy
Chemoradiotherapy, Adjuvant
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms* / drug therapy
Prognosis